RAPT Therapeutics, Inc. (RAPT) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001673772

P/B 2.20

P/E -3.16

P/S 0.00

Market Cap 333.97 Mn

ROIC (Qtr) -69.93

Div Yield % 0.00

Rev 1y % (Qtr) 0.00

Total Debt (Qtr) 2.60 Mn

Debt/Equity (Qtr) 0.02

About

RAPT Therapeutics, Inc. (NASDAQ: RAPT), a clinical-stage biopharmaceutical company, is dedicated to discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. The company's proprietary drug discovery and development engine facilitates the identification of therapeutic targets and the design of selective small molecules that modulate critical immune responses. RAPT Therapeutics' main business activities revolve around the development of oral small molecule...

RAPT Therapeutics, Inc. (NASDAQ: RAPT), a clinical-stage biopharmaceutical company, is dedicated to discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. The company's proprietary drug discovery and development engine facilitates the identification of therapeutic targets and the design of selective small molecules that modulate critical immune responses.

RAPT Therapeutics' main business activities revolve around the development of oral small molecule therapies. The company operates in the biopharmaceutical industry, specifically focusing on inflammatory diseases and oncology. Its operations span across various countries, with a strong presence in the United States.

The company generates revenue through the development and commercialization of its drug candidates. Its primary products include zelnecirnon (RPT193) and tivumecirnon (FLX475). Zelnecirnon is a CCR4 antagonist designed to selectively inhibit the migration of Th2 cells into inflamed tissues, demonstrating promising results in Phase 1b clinical trials. It is being developed to treat various inflammatory diseases, including atopic dermatitis, asthma, chronic obstructive pulmonary disease, chronic spontaneous urticaria, alopecia areata, prurigo nodularis, chronic rhinosinusitis with nasal polyps, allergic rhinitis, and eosinophilic esophagitis.

On the other hand, tivumecirnon is also a CCR4 antagonist, but it is designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors. It has shown encouraging results in Phase 2 clinical trials, demonstrating clinical activity as monotherapy and in combination with the programmed cell death (PD-1) checkpoint inhibitor pembrolizumab in patients with advanced cancer.

RAPT Therapeutics holds a strong position within the industry, boasting a proprietary drug discovery and development engine as one of its key competitive advantages. This engine enables the identification of therapeutic targets and the design of selective small molecules that modulate critical immune responses. Additionally, the company has a strong team with deep expertise in immunology and drug discovery, further supported by extensive capabilities in computational sciences.

The company's customers include patients with inflammatory diseases and cancer, as well as healthcare providers and payers. RAPT Therapeutics is committed to delivering innovative and effective therapies that improve patient outcomes and quality of life.

The brand names and/or trade names of its products include zelnecirnon (RPT193) and tivumecirnon (FLX475). These drug candidates represent the company's commitment to developing innovative and effective therapies for patients with significant unmet needs in inflammatory diseases and oncology.

Stock Price Chart

Analysis

Pros

Healthy cash reserves of 37.93M provide 17.17x coverage of short-term debt 2.21M, demonstrating strong liquidity position and minimal refinancing risk.
Strong tangible asset base of 165.74M provides 63.84x coverage of total debt 2.60M, indicating robust asset backing and low credit risk.
Short-term investments of 119.41M provide solid 13.17x coverage of other current liabilities 9.06M, indicating strong liquidity.
Tangible assets of 165.74M provide robust 18.29x coverage of other current liabilities 9.06M, indicating strong asset backing.
Cash reserves of 37.93M provide robust 2.84x coverage of current liabilities 13.38M, indicating strong short-term solvency.

Cons

Investment activities of (56.70M) provide weak support for R&D spending of 82.87M, which is -0.68x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
Short-term investments of 119.41M significantly exceed cash reserves of 37.93M, which is 3.15x, indicating potentially excessive yield-seeking behavior at the expense of liquidity.
The company's operating cash flow of (86.58M) shows concerning coverage of stock compensation expenses of 18.80M, with a -4.60 ratio indicating potential earnings quality issues.
Free cash flow of (86.66M) provides weak coverage of capital expenditures of 84000, with a -1031.71 ratio suggesting additional external financing needs for growth initiatives.
Operating earnings of (105.64M) show weak coverage of depreciation charges of 3.20M, with a -32.99 ratio indicating high capital intensity and potential reinvestment needs.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SMMT	Summit Therapeutics Inc.	1,349.40 Bn	-1,464.17	0.00	0.01 Bn
2	ONC	BeOne Medicines Ltd.	437.43 Bn	6,381.20	87.97	1.90 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	116.09 Bn	31.59	9.90	1.83 Bn
4	REGN	Regeneron Pharmaceuticals, Inc.	78.10 Bn	17.06	5.48	2.71 Bn
5	ALNY	Alnylam Pharmaceuticals, Inc.	55.87 Bn	1,282.42	17.40	3.21 Bn
6	ARGX	Argenx Se	52.85 Bn	35.08	27,559.65	-
7	BNTC	Benitec Biopharma Inc.	41.75 Bn	-998.33	0.00	0.00 Bn
8	INSM	INSMED Inc	37.80 Bn	-31.93	84.56	0.74 Bn

Industry Comparisons

Current Valuation

Metric	Value	Industry
EV to Assets	1.78	12.31
EV to Cash from Ops.	-3.41	23.25
EV to Debt	113.73	738.44
EV to EBIT	-2.79	-9.16
EV to EBITDA	-2.70	6.95
EV to Free Cash Flow [EV/FCF]	-3.41	21.90
EV to Market Cap	0.88	65.67
EV to Revenue	0.00	227.32
Price to Book Value [P/B]	2.20	22.34
Price to Earnings [P/E]	-3.16	-11.77

Dividend Metrics

Metric	Value	Industry	Percentile
Dividend Coverage Ratio	0.00	-11.94
Dividend Payout Ratio %	0.00	0.16
Dividend per Basic Share	0.00	0.01
FCF Dividend Payout Ratio %	0.00	-0.14
Interest Coverage	0.00	841.00

Growth Metrics

Metric	Value	Industry
Capex Growth (1y) %	55.32	-27.13
Cash and Equivalents Growth (1y) %	0.08	734.65
Dividend Growth (1y) %	0.00	0.01
EBIAT Growth (1y) %	1.73	-46.93
EBITDA Growth (1y) %	1.66	-1.68
EBIT Growth (1y) %	1.73	-56.45
EBT Growth (1y) %	1.73	-12.70
EPS Growth (1y) %	47.76	-28.31
FCF Growth (1y) %	14.03	-31.90
Gross Profit Growth (1y) %	0.00	226.84

Liquidity Ratios

Metric	Value	Industry
Asset Utilization Ratio	0.00	0.14
Cash Payout Ratio	0.00	0.00
Cash Ratio	2.84	3.85
Current Ratio	12.04	7.27
Debt to Equity Ratio	0.02	0.40
Interest Cover Ratio	0.00	841.00
Times Interest Earned	0.00	841.00

Profitability

Metric	Value	Industry	Percentile
EBITDA Margin %	0.00	-18,234.31
EBIT Margin %	0.00	-18,580.80
EBT Margin %	0.00	-19,488.74
Gross Margin %	0.00	-7.59
Net Profit Margin %	0.00	-19,439.22

RAPT Therapeutics, Inc. (NASDAQ: RAPT)